← All tickers

Is BBIO Worth Buying in 2026?

BridgeBio Pharma, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-07

Here’s whether BridgeBio Pharma, Inc. Common Stock (BBIO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.

🔵
Neutral

Positives: trading above the 200-day MA (long-term uptrend intact); RSI 54 — healthy momentum range; strong 1-year return of +76.3%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-0.85% over 10 days). Currently 20.4% off its 52-week high. Score: +2/7.

Ready to act on this? 📈 Trade on Webull

BBIO is holding above its long-term 200-day MA ($66.77) but has slipped below the 50-day MA ($70.60), pointing to short-term weakness in an otherwise intact trend. An RSI of 53.7 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +76.3% compares to +24.4% for SPY (beat the market by 52.0%). The current 20.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $17,634 today
vs. S&P 500 (SPY) — same period beat market by 52.0%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($66.77)
✗Above 50-day MA ($70.60)
✓RSI(14) neutral zone (30–70) — currently 53.7
✓Positive return (+76.3%)
!Within 10% of period high (−20.4%)
Period Range $67.61
$37.69 $84.94
RSI (14) 53.7
0 · OversoldOverbought · 100

Key Metrics

Price$67.61
Period Return+76.3%
Period High$84.94
Period Low$37.69
Drawdown−20.4%
MA-50$70.60
MA-200$66.77
RSI (14)53.7
Avg Volume (30d)3.3M
vs. SPYbeat by 52.0%
Return Rank#262 of 1245

Trade BBIO

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers